• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

CVS Reports Strong First Quarter

Article

Merlo says COVID-19 related business activity added 10 cents to the adjusted earnings per share.

While hospitals, physicians, and other parts of the nation’s healthcare sector are bracing for harsh consequences from COVID-19, the suspension of routine medical care, and a possible economic downturn, insurers and other healthcare companies have reported strong financial results for the first quarter of this year.

Of course most of the first quarter was over before the COVID-19 cases and deaths started to take off in the United States.

CVS officially joined the roster of healthcare companies reporting good first quarters with an earning  report that shows increases in total revenues (up 8.3%), adjusted operating income (up 28%), and adjusted earnings per share (up 18%) compared with the first quarter of 2019.

The company also said today that its projected adjusted earnings per share of between $7.04 and $7.17 for the year remained unchanged.

In earnings call this morning, CEO Larry Merlo said that COVID-19-related business activity added 10 cents to the adjusted earnings per share of $1.91 for the first quarter. Those COVID-19-related business activities included accelerated prescription dispensing, strong “front store revenues” (sales of goods in CVS’ retail stores that are not prescription drugs), and “a modest reduction in discretionary medical utilization,” Merlo said.

Merlo talked up the “higher engagement” of CVS’ “digital assets,” during the call, a trend he said that began in January and accelerated with the outbreak of COVID-19. Merlo cited as example a 600% increase in the utilization of telemedicine for virtual visits through CVS’ Minute Clinics compared with the first quarter of 2019;  a more than 1,000% increase in home delivery of retail prescriptions, and a double-digit percentage increase in app usage across the company’s retail, Caremark, and specialty pharmacy businesses. Merlo said digital refills were up by about 50% in the company’s specialty pharmacy business.

The “health care benefits,” or Aetna, part of the company’s business stood out as an exception to the positive trends. It showed operating income and adjusted operating income decreases of 5.2% and 4.5%, respectively, compared with the first quarter of 2019. The company gave three reasons for these slippages: a decline in the number of people in its commercially insured plans (from almost 3.6 million during the first quarter of 2019  to 3.4 million during the first three months of this year) coupled with a increase in people enrolled in its self-insured plans (an increase of roughly 47,000, from 14,159,000 during the first quarter of 2019 to 14,206,000  during the first quarter of this year); higher Medicaid benefit costs in certain states; and the “incremental operating expense to onboard additional Medicaid members.” CVS acquired Centene’s Medicaid and Medicare Advantage businesses in Illinois last year.

CVS says COVID-19 had a “modest impact” on the health care benefits part of its business during the first quarter of this year. Reduced costs from the deferral of discretionary care was offset, according to the earnings report, by lower net investment income, which fell $71 million, or 43%, from $164 million during the first quarter of 2019 to $93 million during the first quarter of 2020.

Related Videos
Video 6 - "Navigating Insurance Coverage for Prescription Digital Therapeutics"
Video 5 - "FDA Approval Pathway for Prescription Digital Therapeutics"
Video 8 - "Gaps in Evidence Generation for Digital Therapeutics"
Video 7 - "Adoption Lessons For Payers"
Video 10 - "Managing Self Care"
Video 3 - "Embracing and Improving Access to Technology Tools"
Video 4 - "Assessing the Cost-Effectiveness of Prescription Digital Therapeutics "
© 2024 MJH Life Sciences

All rights reserved.